Literature DB >> 27810645

Pre-instillation of tumor microparticles enhances intravesical chemotherapy of nonmuscle-invasive bladder cancer through a lysosomal pathway.

Xun Jin1, Jingwei Ma2, Xiaoyu Liang1, Ke Tang3, Yuying Liu1, Xiaonan Yin1, Yi Zhang1, Huafeng Zhang1, Pingwei Xu3, Degao Chen1, Tianzhen Zhang1, Jinzhi Lu1, Zhuowei Hu4, Xiaofeng Qin5, Xiaoyong Zeng6, Longcheng Li7, Bo Huang8.   

Abstract

Nonmuscle-invasive bladder cancer (NMIBC) is treated with transurethral resection followed by intravesical chemotherapy. However, drug-resistant tumorigenic cells cannot be eliminated, leading to half of the treated cancers recur with increased stage and grade. Innovative approaches to enhance drug sensitivity and eradicate tumorigenic cells in NMIBC treatment are urgently needed. Here, we show that pre-instillation of tumor cell-derived microparticles (T-MP) as natural biomaterials markedly enhance the inhibitory effects of intravesical chemotherapy on growth and hematuria occurrence of orthotropic bladder cancer in mice. We provide evidence that T-MPs enter and increase the pH value of lysosomes from 4.6 to 5.6, leading to the migration of drug-loaded lysosomes along microtubule tracks toward the nucleus and discharging the drugs whereby for the entry of the nucleus. We propose that T-MPs may function as a potent sensitizer for augmenting NMIBC chemotherapy with unprecedented clinical benefits.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder cancer cell; Chemosensitizer; Lysosomes; Microparticles; Recurrence

Mesh:

Substances:

Year:  2016        PMID: 27810645     DOI: 10.1016/j.biomaterials.2016.10.036

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

1.  Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailing pathway.

Authors:  Yanling Sun; Zu'an Zheng; Huafeng Zhang; Yuandong Yu; Jingwei Ma; Ke Tang; Pingwei Xu; Tiantian Ji; Xiaoyu Liang; Degao Chen; Xun Jin; Tianzhen Zhang; Zhixiong Long; Yuying Liu; Bo Huang
Journal:  Oncoimmunology       Date:  2017-03-31       Impact factor: 8.110

2.  SARS-CoV-2 treatment effects induced by ACE2-expressing microparticles are explained by the oxidized cholesterol-increased endosomal pH of alveolar macrophages.

Authors:  Zhenfeng Wang; Jiadi Lv; Pin Yu; Yajin Qu; Yabo Zhou; Li Zhou; Qiangqiang Zhu; Shunshun Li; Jiangping Song; Wei Deng; Ran Gao; Yuying Liu; Jiangning Liu; Wei-Min Tong; Chuan Qin; Bo Huang
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 11.530

Review 3.  Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research.

Authors:  Yan Hu; Yajie Sun; Chao Wan; Xiaomeng Dai; Shuhui Wu; Pui-Chi Lo; Jing Huang; Jonathan F Lovell; Honglin Jin; Kunyu Yang
Journal:  J Nanobiotechnology       Date:  2022-04-13       Impact factor: 10.435

Review 4.  Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond.

Authors:  Yu-Ru Liu; Carlos J Ortiz-Bonilla; Yi-Fen Lee
Journal:  Int J Mol Sci       Date:  2018-09-18       Impact factor: 5.923

Review 5.  Engineered extracellular vesicles: potentials in cancer combination therapy.

Authors:  Jiangbin Chen; Qi Tan; Zimo Yang; Yang Jin
Journal:  J Nanobiotechnology       Date:  2022-03-15       Impact factor: 10.435

Review 6.  Tumor-derived microparticles in tumor immunology and immunotherapy.

Authors:  Jingwei Ma; Huafeng Zhang; Ke Tang; Bo Huang
Journal:  Eur J Immunol       Date:  2020-10-28       Impact factor: 5.532

Review 7.  Recent progress in targeted delivery vectors based on biomimetic nanoparticles.

Authors:  Li Chen; Weiqi Hong; Wenyan Ren; Ting Xu; Zhiyong Qian; Zhiyao He
Journal:  Signal Transduct Target Ther       Date:  2021-06-07

Review 8.  Cytoskeletal prestress: The cellular hallmark in mechanobiology and mechanomedicine.

Authors:  Farhan Chowdhury; Bo Huang; Ning Wang
Journal:  Cytoskeleton (Hoboken)       Date:  2021-05-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.